Repeated short cycles of nonsteroidal anti-inflammatory drugs and kidney injury in patients with spinal degenerative-dystrophic diseases

Objective: to evaluate kidney function in patients with spinal degenerative-dystrophic diseases (SDDDs) who take nonsteroidal anti-inflammatory drugs (NSAIDs) as repeated short cycles of treatment for severe back pain.

Patients and methods. The investigation enrolled 97 patients with SDDDs who took NSAIDs for back pain (a study group). A control group consisted of sexand age-matched healthy individuals who had not used NSAIDs within the past year (n=40). Glomerular filtration rate (GFR) was estimated using the CKD-EPI equation and markers of kidney injury (albuminuria and globulinuria) were measured.

Results. In the study group, GFR was decreased to <90 ml/min/1.73 m2 in 61 (62.9%) patients, to <60 ml/min/1.73 m2 in 11 (11.3%); the mean GFR was 77.5 [68.0; 89.0] ml/min/1.73 m2; in the control group, a decline in GFR to 89–60 ml/min/1.73 m2 was recorded in 35 (62.5%) cases; this indicator was >90 ml/min/1.73 m2 in the remaining 15 (37.5%) cases; the mean GFR was 82.5 [70.8; 90.0] ml/min/1.73 m2 (p≥0.05 for all pairwise comparisons). A decrease in GFR to <60 ml/min/1.73 m2 was found in 11 (11.3%) patients in the study group and in nobody in the control group (p=0.026). Elevated albuminuria was noted in 74 (76.3%) patients with SDDDs and in 9 (22.5%) healthy individuals (p<0.05). Albumin/creatinine ratio was 57.1 [33.8; 82.4] mg/g in the study group and 25.0 [17.5; 32.9] mg/g in the control group (p<0.0001). Increased globulinuria was established in all the patients with SDDDs and only in 3 (7.5%) healthy examinees. Globulin/creatinine ratio was 134.7 [77.5; 197.7] mg/g in the study group and 12.9 [0.5; 18.1] mg/g in the control group (p<0.0001).

Conclusion. A decline in GFR to <60 ml/min/1.73 m2 was more often seen in the patients taking NSAIDs for spine pain caused by SDDDs than in the healthy individuals. In case of comparable GFR, the level of kidney injury markers was significantly higher in the study group than that in the control group, which suggests that patients with SDDDs who take NSAIDs have subclinical tubulointerstitial and glomerular changes.

1. Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011 Nov;70(11):1921-5. doi: 10.1136/ard.2011.151191. Epub 2011 Jul 21.

2. Bennet WM, Burdmann EA, Andoh TE, et al. Nephrotoxicity of immunosuppressive drugs. Nephrol Dial Transplant. 1994;9 Suppl 4:141-5.

3. Cao YL, Tian ZG, Wang F, et al. Characteristics and clinical outcome of nonsteroidal anti-inflammatory drug-induced acute hepatonephrotoxicity among Chinese patients. World J Gastroenterol. 2014 Oct 14;20(38): 13956-65. doi: 10.3748/wjg.v20.i38.13956.

4. Hsu CC, Wang H, Hsu YH, et al. Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. Hypertension. 2015 Sep;66(3): 524-33. doi: 10.1161/HYPERTENSIONHA.114.05105. Epub 2015 Jul 13.

5. Ingrasciotta Y, Sultana J, Giorgianni F, et al. The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. PLoS One. 2014 Feb 18;9(2):e89072. doi: 10.1371/journal.pone.0089072.eCollection2014.

6. Matsushita K, van der Velde M, Astor BC, et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010 Jun 12; 375(9731):2073-81. doi: 10.1016/S01406736(10)60674-5. Epub 2010 May 17.

7. Gaidukova IZ, Rebrov AP, Lebedinskaya OA, et al. Chronic kidney disease in patients with chronic back pain taking nonsteroidal antiinflammatory drugs. Saratovskii nauchno-meditsinskii zhurnal. 2016;(1):40-4. (In Russ.).

8. Kirshina NS, Pimenov LT. Phasing of renal dysfunction and anemia in patients with chronic heart failure. Rossiiskii kardiologicheskii zhurnal. 2009;(3): 21–5. (In Russ.).

9. Shvetsov MYu, Bobkova IN, Kolina IB, Kamyshova ES. Khronicheskaya bolezn' pochek i nefroprotektivnaya terapiya [Chronic kidney disease and renal protection therapy]. Moscow; 2012. 78 p.

10. Matsionis AE, Batyushin MM, Povilaitite PE, Litvinov AS. Morphological analysis of pathological changes in the kidneys depending on the duration of arterial hypertension. Nefrologiya. 2007;20(3):53–6. (In Russ.).

11. Nephrology: guidelines for physicians]. Moscow: Meditsina; 2000. 688 p.

12. Shishkin AN. Analgesic nephropathy: a hidden threat. Novye SanktPeterburgskie vrachebnye vedomosti. 2003;(2): 28–31. (In Russ.).

13. Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12.

14. Dougados M, Wood E, Gossec L, et al. Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drugsparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis. J Rheumatol. 2015 Dec;42(12):2361-8. doi: 10.3899/jrheum.150378. Epub 2015 Nov 15. doi:10.3899/jrheum.150378.

15. Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens. 2002 Mar;20(3):353-5.

16. Raine AE. Hypertension and the kidney. Br Med Bull. 1994 Apr;50(2):322-41.

17. Pinto-Sietsma SJ, Janssen WM, Hillege HL, et al. Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol. 2000 Oct;11(10):1882-8.

18. Kistorp C, Raymond I, Pedersen F, et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005 Apr 6;293 (13):1609-16. doi: 10.1001/jama.293.13.1609

19. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep 23;351(13):1296-305. doi: 10.1056/NEJMoa041031.